Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity

Current Opinion in Investigational Drugs

Volumn 10, Issue 10, 2009, Pages 1105-1116

  Bello, N T ^a   Zahner, M R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMFEBUTAMONE; ANTIOBESITY AGENT; ATOMOXETINE; CARBIDOPA; DEXAMPHETAMINE; DONEPEZIL; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SIBUTRAMINE; TESOFENSINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGER; ANXIETY DISORDER; BODY FAT; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; HALLUCINATION; HARD FECES; HEART RATE; HOSTILITY; HUMAN; HYPOTENSION; INSOMNIA; NAUSEA; NONHUMAN; OBESITY; PARKINSON DISEASE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; OBESITY; RATS; WEIGHT LOSS;

EID: 70349739420     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. 186856 A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: Evidence that dopamine is not a pharmacological target for sibutramine. Heal DJ, Frankland AT, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, Buckett WR PSYCHOPHARMACOLOGY 1992 107 2-3 303-309
2. 202006 Synthesis, cocaine receptor affinity, and dopamine uptake inhibition of several new 2 β-substituted 3 β-phenyltropanes. Kelkar SV, Izenwasser S, Katz JL, Klein CL, Zhu N, Trudell ML J MED CHEM 1994 37 23 3875-3877
3. 261454 NeuroSearch commences phase I clinical trial of NS-2330 for treatment of dementia. NEUROSEARCH A/S PRESS RELEASE 2007 September 04
4. 263232 Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ BR J PHARMACOL 1997 121 8 1613-1618
5. 266764 Behavior of tetrahydrolipstatin in biological model membranes and emulsions. Ko J, Small DM J LIPID RES 1997 38 8 1544-1552
6. 278590 In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor. Gundlah C, Martin KF, Heal DJ, Auerbach SB J PHARMACOL EXP THER 1997 283 2 581-591
7. 347738 First main cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers. Jones S, Jensen NO, Oliver S, Wesnes KA J PSYCHOPHARMACOL 1999 13 3 Suppl A A26
8. 364760 Cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers. Wills K, Jensen NO, Oliver S, Wesnes KA J PSYCHOPHARMACOL 1999 13 3 Suppl A A27
9. 439172 NeuroSearch teams with Boehringer to progress NS-2330 NeuroSearch AS PRESS RELEASE 2002 February 08
10. 444735 Meridia fatality rate 'substantially lower' than obese population - Abbott. FDC REP PINK SHEET 2001 64 12 21
11. 526982 NeuroSearch A/S Annual Report 2003: Part 1. NeuroSearch A/S PRESS RELEASE 2005 March 10
12. 617227 Boehringer Ingelheim discontinues NS-2330 for Alzheimer's NeuroSearch A/S PRESS RELEASE 2005 August 10
13. 647038 NeuroSearch continues the development of tesofensine (NS2330) and Boehringer Ingelheim returns all rights to NeuroSearch. NeuroSearch A/S PRESS RELEASE 2006 January 25
14. 680001 NeuroSearch A/S: Annual Report 2005 NeuroSearch A/S ANNUAL REPORT 2006 March 08
15. 734011 NeuroSearch buys A Carlsson for $35.4 million NeuroSearch A/S PRESS RELEASE 2006 October 23
16. 775946 Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD EUR J PHARMACOL 2007 555 2-3 115-121
17. 831011 NeuroSearch announces breakthrough tesofensine results from clinical phase IIb study in obesity ('TIPO-1'). NeuroSearch A/S PRESS RELEASE 2007 September 17
18. 865181 Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW BMJ MED J 2007 335 7631 1194-1199
19. 865890 Cardiovascular responses to weight management and sibutramine in high-risk subjects: An analysis from the SCOUT trial. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P EUR HEART J 2007 28 23 2915-2923
20. 867724 Obesity drug sibutramine (Meridia): Hypertension and cardiac arrhythmias. Wooltorton E CMAJ 2002 166 10 1307-1308
21. 871361 Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modelling approach. Lehr T, Staab A, Tillmann C, Nielsen EO, Trommeshauser D, Schaefer HG, Kloft C BR J PHARMACOL 2008 153 1 164-174 •• Presents data from a preclinical study in which tesofensine and M1 were administered orally and intravenously to mice. M1 was determined to have higher trough plasma concentrations but lower inhibition potency for the DA transporter compared with tesofensine.
22. 882370 NeuroSearch publishes positive and confirmatory results from TIPO-2, a clinical metabolic study with tesofensine for the treatment of obesity. NEUROSEARCH A/S PRESS RELEASE 2008 March 03
23. 908985 Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T ARCH NEUROL 2008 65 6 577-583
24. 955619 The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2008 October 23
25. 955661 Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM LANCET 2008 372 9653 1906-1913 •• Presents data from a phase II, 24-week clinical trial (TIPO-1) of tesofensine in 203 obese individuals. Weight loss and increasing heart rate were dose-dependent, whereas blood pressure was elevated only at the highest dose.
26. 959927 Drug development update: Rimonabant. sanofi-aventis COMPANY COMMUNICATION 2008 November 06
27. 966849 NeuroSearch announces highly positive and supportive final results from a cardiovascular safety evaluation study with the anti-obesity drug tesofensine 26 November 2008 - Announcement. NeuroSearch A/S PRESS RELEASE 2008 November 26
28. 1003480 Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM OBESITY (SILVER SPRING) 2008 16 6 1363-1369 • Presents a meta-analysis of four randomized, double-blind, multicenter clinical trials in patients with AD or PD (n = 968). Daily tesofensine produced significant weight loss after 14 weeks of treatment without any supporting weight management program.
29. 1003481 The effect of tesofensine on weight loss, appetite, physical activity and QOL in obese subjects. Results from a 24-week randomised, double-blind placebo-controlled trial. Astrup A, Madsbad S, Breum L, Kroustrup JP, Jensen TJ, Larsen TM DIABETES 2008 57 Suppl 1 A739
30. 1003482 The effects of tesofensine on body composition in obese subjects. Sjodin A, Gasteyger C, Nielsen A-LH, Madsbad S, Breum L, Kroustrup JP, Jensen TJ, Meier DH, Mikkelsen BO, Larsen TM, Astrup A INT J OBESITY 2008 32 Suppl 1 S83
31. 1003483 The efficacy and safety of tesofensine for weight loss in obese subjects. A 24-week randomised, double-blind, placebo-controlled Danish multi-centre trial. Astrup A, Madsbad S, Breum L, Kroustrup JP, Jensen TJ, Larsen TM INT J OBESITY 2008 32 Suppl 1 S23
32. 1003484 Randomized trial of the triple monoamine reuptake inhibitor NS-2330 (tesofensine) in early Parkinson's disease. Hauser RA, Salin L, Juhel N, Konyago VL MOV DISORD 2007 22 3 359-365
33. 1003485 Population pharmacokinetic modelling of NS-2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C BR J CLIN PHARMACOL 2007 64 1 36-48 •• Demonstrated that plasma-concentration data from patients with AD undergoing daily treatment were best fitted to a one-compartment pharmacokinetic model for tesofensine and the M1 metabolite. The t1/2 values of tesofensine and M1 were determined to be 234 and 374 h, respectively.
34. 1003486 Effect of monoamine reuptake inhibitor NS-2330 in advanced Parkinson's disease. Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN MOV DISORD 2004 19 10 1183-1186
35. 1008166 Supportive clinical data on tesofensine, NeuroSearch's late-stage anti-obesity drug, presented at the 17th European Congress on Obesity. NeuroSearch A/S PRESS RELEASE 2009 May 07
36. 1016291 NeuroSearch successfully completes end of phase II meeting with the FDA for tesofensine, a treatment for obesity. NeuroSearch A/S PRESS RELEASE 2009 June 08 • Summarizes the findings from phase II clinical trials for tesofensine and outlines the objectives for the phase III program.
37. 1021431 The effect of tesofensine on weight loss: Results from a one-armed, open-labelled extension study. Astrup A, Madsbad S, Breum L, Kroustrup JP, Raben A, Jensen J-KS, Meier D, Sjodin A, NeuroSearch A/S COMPANY PUBLICATION 2009 May 07
38. 1021434 Tesofensine a novel weight management drug has no or minimal abuse potential. Schoedel KA, Meier D, Chakraborty B, Manniche P, Sellers EM, NeuroSearch A/S COMPANY PUBLICATION 2009 May 07
39. 1021473 NS2330 enhances cognitive function in both normal volunteers and elderly volunteers with possible Alzheimer's disease. Wesnes KA, Preskorn SH, Friesen S, Edgar C, Mikkelsen BO, NeuroSearch A/S COMPANY PUBLICATION 2001 November 31
40. 1021502 The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Sjodin A, Gasteyger C, Nielsen ALH, Raben A, Mikkelsen JD, Jensen JK, Meier D, Asrtup A OBES FACTS 2009 2 S2 T5:RS3.3
41. 1022138 Tesofensine. NeuroSearch A/S COMPANY WORLD WIDE WEB SITE 2009 June 26
42. 1027525 Is body mass index before middle age related to coronary heart disease risk in later life? Evidence from observational studies. Owen CG, Whincup PH, Orfei L, Chou QA, Rudnicka AR, Wathern AK, Kaye SJ, Eriksson JG, Osmond C, Cook DG INT J OBES 2009 33 8 866-877
43. 1027527 Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R, Lewington S, MacMahon S et al LANCET 2009 373 9669 1083-1096
44. 1027528 American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB et al SURG OBES RELAT DIS 2008 4 5 Suppl S109-S184
45. 1027541 Drug therapy - Obesity. Yanovski SZ, Yanovski JA N ENGL J MED 2002 346 8 591-602 • Discusses pharmacological and non-pharmacological approaches for the treatment of obesity. In addition, reviews some of the herbal and natural supplement treatments available for appetite suppression and weight reduction.
46. 1027542 Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Hadvary P, Lengsfeld H, Wolfer H BIOCHEM J 1988 256 2 357-361
47. 1027544 Central nervous system biogenic amine targets for control of appetite and energy expenditure. Nelson DL, Gehlert DR ENDOCRINE 2006 29 1 49-60 • Reviews the literature on current and past monoamine-targeted pharmacotherapies for obesity; provides useful comparison tables and some discussion of the SAR for each major class of compounds.
48. 1027547 Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, Buckett WR PSYCHOPHARMACOLOGY 1990 100 3 345-349
49. 1027548 The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Walsh KM, Leen E, Lean ME INT J OBES RELAT METAB DISORD 1999 23 10 1009-1015
50. 1027550 The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A INT J OBES RELAT METAB DISORD 1999 23 10 1016-1024
51. 1027569 The effect of weight-reduction on left-ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. MacMahon SW, Wilcken DE, Macdonald GJ N ENGL J MED 1986 314 6 334-339
52. 1027572 Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? A population-based cohort study of more than one million Swedish men. Silventoinen K, Magnusson PK, Neovius M, Sundstrom J, Batty GD, Tynelius P, Rasmussen F CIRCULATION 2008 118 16 1637-1642
53. 1027580 Influence of sibutramine on blood pressure: Evidence from placebo-controlled trials. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM INT J OBESITY (LOND) 2005 29 5 509-516 •• Presents a combined analysis of the results of two multicenter clinical trials with sibutramine. Doses of sibutramine that effectively decreased body weight in the 48-week period were associated with an increase in supine heart rate of approximately 3 bpm and an increase in diastolic blood pressure of 1.1 mmHg.
54. 1027583 N-modified analogs of cocaine - Synthesis and inhibition of binding to the cocaine receptor. Abraham P, Pitner JB, Lewin AH, Boja JW, Kuhar MJ, Carroll FI J MED CHEM 1992 35 1 141-144
55. 1027586 The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR NEUROPHARMACOLOGY 1989 28 2 129-134
56. 1027589 NICE requires primary care trusts to tackle prevention and management of obesity. Mayor S BMJ (CLINICAL RES ED) 2006 333 7581 1239
57. 1027615 Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: A hypothesis. Seeman P, Madras B BEHAV BRAIN RES 2002 130 1-2 79-83
58. 1027616 Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior - Theoretical and clinical implications. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA ANN NY ACAD SCI 1989 575 171-193
59. 1027618 Dopamine transporter ligands: Recent developments and therapeutic potential. Runyon SP, Carroll FI CURR TOP MED CHEM 2006 6 17 1825-1843
60. 1027622 Brain-derived neurotrophic factor (BDNF) and food intake regulation: A minireview. Lebrun B, Bariohay B, Moyse E, Jean A AUTON NEUROSCI 2006 126-127 30-38
61. 1028827 World Health Organization - Obesity and overweight fact sheet no 311. WHO INTERNET SITE 2006 September 30
62. 1028843 National Institutes of Health; National Heart, Lung, and Blood Institute; NHLBI Obesity Education Initiative; North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH INTERNET SITE 2000 October 31
63. 1028899 The European Agency for the Evaluation of Medicinal Products. Post-authorisation evaluation of medicines for human use. Committee for Proprietary Medicinal Products opinion following an Article 31 referral - Sibutramine. EMEA EMEA PUBL 2002 December 02
64. 1028945 Piper Jaffray Europe Conference. NeuroSearch A/S COMPANY PRESENTATION 2009 June 23
65. 1036311 Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH NEPHRON 1976 16 1 31-41
66. 1036313 Gender differences in the membrane transport of endogenous and exogenous compounds. Morris ME, Lee HJ, Predko LM PHARMACOL REV 2003 55 2 229-240